Market Closed -
Nasdaq
04:30:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.4889
USD
|
+1.88%
|
|
+7.24%
|
-59.26%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Capitalization
1 |
178.4
|
192.9
|
103.5
|
23.53
|
12.76
|
12.76
|
Enterprise Value (EV)
1 |
142.6
|
147.7
|
89.51
|
23.53
|
12.76
|
12.76
|
P/E ratio
|
-6.91
x
|
-8.65
x
|
-2.23
x
|
-0.73
x
|
-0.29
x
|
-0.47
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.66
x
|
1.5
x
|
0.55
x
|
0.5
x
|
0.26
x
|
0.21
x
|
EV / Revenue
|
3.66
x
|
1.5
x
|
0.55
x
|
0.5
x
|
0.26
x
|
0.21
x
|
EV / EBITDA
|
-31,367,726
x
|
178,162,448
x
|
-6,197,921
x
|
-
|
-
|
-
|
EV / FCF
|
-24,510,615
x
|
-185,886,254
x
|
-4,198,819
x
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
Price to Book
|
2.98
x
|
2.81
x
|
3.8
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
19,861
|
21,861
|
22,511
|
27,082
|
27,866
|
27,866
|
Reference price
2 |
8.982
|
8.826
|
4.598
|
0.8690
|
0.4580
|
0.4580
|
Announcement Date
|
4/23/20
|
4/15/21
|
3/30/22
|
5/16/23
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net sales
1 |
40.48
|
48.78
|
128.4
|
189.9
|
47.47
|
48.62
|
59.5
|
EBITDA
|
-
|
-5.687
|
1.083
|
-16.7
|
-
|
-
|
-
|
EBIT
1 |
-
|
-18.68
|
-19.7
|
-46.03
|
-36.77
|
-42.55
|
-39.6
|
Operating Margin
|
-
|
-38.3%
|
-15.35%
|
-24.24%
|
-77.46%
|
-87.51%
|
-66.55%
|
Earnings before Tax (EBT)
1 |
-
|
-20.7
|
-21.1
|
-46.88
|
-38.6
|
-48.63
|
-45.38
|
Net income
1 |
-
|
-20.86
|
-21.38
|
-46.9
|
-31.84
|
-48.65
|
-45.38
|
Net margin
|
-
|
-42.75%
|
-16.65%
|
-24.7%
|
-67.07%
|
-100.05%
|
-76.27%
|
EPS
2 |
-40.00
|
-1.300
|
-1.020
|
-2.060
|
-1.190
|
-1.600
|
-0.9700
|
Free Cash Flow
|
-
|
-7.278
|
-1.038
|
-24.65
|
-
|
-
|
-
|
FCF margin
|
-
|
-14.92%
|
-0.81%
|
-12.98%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/28/19
|
4/23/20
|
4/15/21
|
3/30/22
|
5/16/23
|
-
|
-
|
Fiscal Period: December |
2021 Q1
|
2021 Q2
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
---|
Net sales
1 |
64.96
|
51.87
|
30.2
|
42.9
|
10.33
|
11.2
|
-
|
11.5
|
12.5
|
14
|
14.5
|
15
|
EBITDA
|
0.698
|
-2.066
|
-12.68
|
-2.654
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.63
|
-7.684
|
-21.35
|
-12.37
|
-
|
-10.84
|
-
|
-10.8
|
-10.5
|
-10.1
|
-10
|
-9.9
|
Operating Margin
|
-7.13%
|
-14.81%
|
-70.69%
|
-28.83%
|
-
|
-96.76%
|
-
|
-93.91%
|
-84%
|
-72.14%
|
-68.97%
|
-66%
|
Earnings before Tax (EBT)
1 |
-4.889
|
-7.896
|
-21.61
|
-12.48
|
-
|
-11.71
|
-
|
-12.24
|
-11.94
|
-11.54
|
-11.44
|
-11.34
|
Net income
1 |
-4.889
|
-8.222
|
-21.61
|
-12.3
|
-6.482
|
-10.35
|
-24.46
|
-12.24
|
-11.94
|
-11.54
|
-11.44
|
-11.34
|
Net margin
|
-7.53%
|
-15.85%
|
-71.57%
|
-28.67%
|
-62.77%
|
-92.41%
|
-
|
-106.48%
|
-95.56%
|
-82.46%
|
-78.93%
|
-75.63%
|
EPS
2 |
-0.2200
|
-0.3700
|
-0.9600
|
-0.5100
|
-0.2800
|
-0.3800
|
-0.8800
|
-0.4400
|
-0.3400
|
-0.2700
|
-0.2700
|
-0.2400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/16/21
|
9/7/21
|
11/24/21
|
3/30/22
|
7/15/22
|
12/22/22
|
9/7/23
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
35.8
|
45.3
|
14
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-7.28
|
-1.04
|
-24.7
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-35.4%
|
-34.1%
|
-101%
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-17.7%
|
-16%
|
-38.9%
|
-
|
-
|
-
|
Assets
1 |
-
|
117.5
|
133.8
|
120.5
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
3.010
|
3.140
|
1.210
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-0.4700
|
0.4000
|
-0.9700
|
-
|
-
|
-
|
Capex
|
-
|
0.3
|
9.5
|
2.92
|
0.37
|
-
|
-
|
Capex / Sales
|
-
|
0.61%
|
7.4%
|
1.54%
|
0.77%
|
-
|
-
|
Announcement Date
|
3/28/19
|
4/23/20
|
4/15/21
|
3/30/22
|
5/16/23
|
-
|
-
|
Last Close Price
0.458
EUR Average target price
1.378
EUR Spread / Average Target +200.90% Consensus |
1st Jan change
|
Capi.
|
---|
| -59.26% | 13.62M | | +1.51% | 42.75B | | +8.57% | 41.34B | | +49.22% | 41.61B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|